艾曲泊帕治疗慢性原发免疫性血小板减少症的效果及安全性分析  

Efficacy and Safety Analysis of Eltrombopag in Treatment of Chronic Primary Immune Thrombocytopenia

作　　者：苏璟 梁颖[2] 刘春雨[2] 张璐[2] 宋可威 陈楠楠[1,2] Su Jing;Liang Ying;Liu Chun-yu;Zhang Lu;Song Ke-wei;Chen Nan-nan(Postgraduate Training Base,967th Hospital of the People's Liberation Army Joint Services and Security Forces,Dalian 116011,Liaoning Province,China;Department of Hematology,967th Hospital of the People's Liberation Army Joint Services and Security Forces,Dalian 116011,Liaoning Province,China)

机构地区：[1]中国人民解放军联勤保障部队第九六七医院研究生培养基地,辽宁大连116011 [2]中国人民解放军联勤保障部队第九六七医院血液科,辽宁大连116011

出　　处：《中国社区医师》2022年第32期71-73,共3页Chinese Community Doctors

摘　　要：目的:研究艾曲泊帕治疗慢性原发免疫性血小板减少症的效果及安全性。方法:选取2019年9月-2021年9月中国人民解放军联勤保障部队第九六七医院收治的60例慢性原发免疫性血小板减少症患者作为研究对象,按照随机数字表法分为观察组和对照组,各30例。对照组应用地塞米松进行治疗,观察组在对照组基础上给予艾曲泊帕进行治疗。比较两组患者用药至恢复正常时间、血小板计数峰值时间、并发症发生率。结果:观察组患者用药至恢复正常时间、血小板计数峰值时间均短于对照组,差异有统计学意义(P<0.05)。两组患者并发症发生率比较,差异无统计学意义(P>0.05)。结论:慢性原发免疫性血小板减少症患者应用艾曲泊帕进行治疗,能够有效改善临床指标,效果显著,安全性高,值得推广。Objective:To study the efficacy and safety of eltrombopag in the treatment of chronic primary immune thrombocytopenia.Methods:Sixty patients with chronic primary immune thrombocytopenia admitted to the 967th Hospital of the People's Liberation Army Joint Services and Security Forces from September 2019 to September 2021 were selected as study subjects.According to the random number table method,they were divided into observation group and control group,30 cases each.The control group was treated with dexamethasone,and the observation group was treated with eltrombopag on the basis of the control group.The time from medication to return to normal,the time to peak platelet count,and the incidence of complications were compared between the two groups.Results:The time from medication to normalization and the peak platelet count time were shorter in the observation group than in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference between the incidence of complications in the two groups(P>0.05).Conclusion:The treatment of patients with chronic primary immune thrombocytopenia with eltrombopag can effectively improve the clinical indexes with significant effect and high safety,which is worth promoting.

关 键 词：艾曲泊帕 慢性原发免疫性血小板减少症 安全性 

分 类 号：R558.2[医药卫生—血液循环系统疾病]